Filing Details
- Accession Number:
- 0001209191-20-024228
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-04-13 17:15:10
- Reporting Period:
- 2020-04-13
- Accepted Time:
- 2020-04-13 17:15:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1664710 | Keros Therapeutics Inc. | KROS | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1808244 | Alon Lazarus | C/O Keros Therapeutics, Inc. 99 Hayden Avenue, Suite 120, Building E Lexington MA 02421 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-04-13 | 1,382,295 | $0.00 | 1,382,295 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-04-13 | 343,270 | $0.00 | 1,725,565 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-04-13 | 167,537 | $0.00 | 1,893,102 | No | 4 | C | Indirect | See footnote |
| Common Stock | Acquisiton | 2020-04-13 | 120,000 | $16.00 | 2,013,102 | No | 4 | P | Indirect | See footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | C | Indirect | See footnote |
| No | 4 | P | Indirect | See footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2020-04-13 | 1,382,295 | $0.00 | 1,382,295 | $0.00 |
| Common Stock | Series B-1 Preferred Stock | Disposition | 2020-04-13 | 343,270 | $0.00 | 343,270 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2020-04-13 | 167,537 | $0.00 | 167,537 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 23,038 | Direct |
Footnotes
- Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.
- The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. The Reporting Person, a member of the board of directors of the Issuer, is the Biotech Investment Manager of the Pharma Division of Arkin Holdings, and, as a result, may be deemed to share voting and investment power with respect to the shares held by Arkin Bio. The Reporting Person disclaims beneficial ownership of the shares held by Arkin Bio, except to the extent of his pecuniary interest therein.
Billionaire Hedge Funds
